CTLA4 and melanoma: The real breakthrough in melanoma patients’ treatment with metastasis was the biological activity of monoclonal antibodies working as immunomodulators, like ipilimumab or nivolumab, blocking the repressor of T lymphocyte activation (CTLA-4) and programmed cell death protein (PD-1).